Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity
– Series A financing led by Catalio Capital Management, Third Rock Ventures and Novo Holdings – Platform enables modular T cell engagers tailored to oncogenic driver mutations for highly specific tumor targeting – Founders include cancer genetics pioneer…